Snider Morgan E, Nuzum Donald S, Veverka Angie
Virginia Commonwealth University Health Systems, Richmond, VA, USA.
Vasc Health Risk Manag. 2008;4(6):1249-57. doi: 10.2147/vhrm.s3661.
Hypertension is a global condition affecting billions worldwide. It is a significant contributor to cardiovascular events, cardiac death and kidney disease. A number of medication classes exist to aid healthcare providers and their patients in controlling hypertension. Nifedipine, a dihydropyridine calcium channel blocker, was once one of the most widely used medications for hypertension, but safety and tolerability concerns along with the introduction of new classes of antihypertensive medications and an increasing pool of data showing mortality benefit of other classes caused nifedipine to fall out of favor. More recently, long-acting formulations were developed and made available to clinicians. These newer formulations were designed to address many of the concerns raised by earlier formulations of nifedipine. Numerous clinical trials have been conducted comparing long-acting nifedipine to many of the more commonly prescribed antihypertensive medications. This review will address the pharmacology, pharmacokinetics and the available clinical trial data on long-acting nifedipine and summarize its role in the management of hypertension.
高血压是一种全球性疾病，影响着全球数十亿人。它是心血管事件、心脏死亡和肾脏疾病的重要促成因素。有多种药物类别可帮助医疗保健提供者及其患者控制高血压。硝苯地平是一种二氢吡啶类钙通道阻滞剂，曾是治疗高血压最广泛使用的药物之一，但由于安全性和耐受性问题，以及新型抗高血压药物的推出和越来越多的数据表明其他类药物具有降低死亡率的益处，硝苯地平不再受到青睐。最近，长效制剂被开发出来并可供临床医生使用。这些更新的制剂旨在解决早期硝苯地平制剂引发的许多问题。已经进行了大量临床试验，将长效硝苯地平与许多更常用的抗高血压药物进行比较。本综述将阐述长效硝苯地平的药理学、药代动力学和现有临床试验数据，并总结其在高血压管理中的作用。
